EMA Authorised: Quadramet (samarium (153Sm) lexidronam pentasodium) — CIS bio international

View source ↗

Summary

EMA authorised Quadramet (samarium-153 lexidronam pentasodium) for the palliation of bone pain in cancer patients with bone metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases

Drugs mentioned

• Quadramet (samarium-153 lexidronam pentasodium)

Snippet

Status: Authorised. Therapeutic area: Pain;Cancer. MAH: CIS bio international. Decision date: 04/09/2025